热烧伤患者伏立康唑与泊沙康唑给药方案评估
该回顾性研究纳入2014年4月至2020年4月成年热烧伤患者,评估伏立康唑和泊沙康唑初始给药方案达到治疗性稳态谷浓度的比例。33例中26例(78.8%)在唑类治疗期间达到治疗水平,但仅11例(33.3%)在初始方案即达标,中位达标时间8.0±21.8天。热烧伤患者唑类最优给药策略仍未明确。
要点
- 仅33.3%热烧伤患者初始唑类方案即达治疗性稳态谷浓度。
- 78.8%患者在整个唑类治疗期间可达治疗水平,但中位延迟8.0±21.8天。
- 热烧伤患者唑类最优给药策略未定义,需进一步评估患者特异性因素。
核心结论
- 热烧伤患者中仅少数在初始唑类方案即达到治疗性稳态谷浓度,多数需调整后达标,最优给药策略仍未明确。
研究设计与样本
- 回顾性评估2014年4月至2020年4月成年热烧伤患者,分析伏立康唑和泊沙康唑给药方案,共33例。
主要发现
- 33例中26例(78.8%)在唑类治疗期间达到治疗性水平。
- 仅11例(33.3%)在初始唑类方案达到治疗性水平。
- 从唑类治疗开始至达到治疗水平的中位时间为8.0±21.8天。
临床怎么用
- 热烧伤患者使用伏立康唑或泊沙康唑时应警惕初始方案达标率低,需监测稳态谷浓度并考虑延迟达标风险。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fungal infections are a recognized cause of increased morbidity and mortality in thermal burn patients. Adequate treatment regimens remain a challenge due to unpredictable pharmacokinetic/pharmacodynamic changes caused by a hypermetabolic state and individual patient factors. A retrospective evaluation of adult thermal burn patients from April 2014 to April 2020 was conducted to assess voriconazole and posaconazole antifungal dosing regimens. The primary outcome was the incidence of attaining a therapeutic steady-state trough level on the patient's initial voriconazole or posaconazole regimen. Of the 33 patients analyzed, 26 (78.8%) patients achieved a therapeutic level during azole therapy. However, only 11 (33.3%) patients achieved a therapeutic level on their first azole regimen. The median time to therapeutic level was 8.0 + 21.8 days from the start of azole therapy. Optimal dosing strategies for azole therapy in patients with thermal burns remain undefined. Further assessment is needed to delineate patient-specific factors that can contribute to subtherapeutic azole levels in thermal burn patients and the overall clinical impact of population-specific dosing regimens.
引用
- Musick KL, Jones SL, Norris AM, et al. Evaluation of Voriconazole and Posaconazole Dosing in Patients With Thermal Burn Injuries. J Burn Care Res. 2022. PMID: 34672325. doi:10.1093/jbcr/irab200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。